John P. Diaz, MD, provides an overview of the topics to be discusses during the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.
John P. Diaz, MD, the chief of Gynecologic Oncology, lead physician for Clinical Trials in Gynecologic Oncology at MCI, and chief of the Center of Excellence in Minimally Invasive Gynecologic Surgery, Baptist Health South Florida, provides an overview of the topics to be discusses during the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.
The symposium, which is being held at Hilton Miami Dadeland in Miami, Florida, will include presentations on prevention, and management of gynecologic cancers as well as breast cancers. Presenters will also provide insights on the future landscapes for women’s cancers.
0:08 | This is our third Women's Cancer post that we've held here at the Miami Cancer Institute. There's been a lot of advances in ovarian cancer, endometrial cancer, and cervical cancer over the last couple years we thought was a great time to once again, hold our symposium and bring experts from across United States together to discuss the updates on these three most common gynecologic cancers.
0:30 | We just got back from the Society of Gynecologic Oncology Annual Meeting, and we had great presentations on the role of immunotherapy in the treatment of endometrial cancer. For several years now we've been looking at who are the best patients to derive benefit from therapy. Can we use immunotherapy in combination with other treatments like traditional chemotherapy for the treatment of these women? And can we move it up to the primary and frontline treatment of these women? So, at the SGO Annual Meeting, a few weeks ago in Tampa, Florida, 2 sentinel presentations were made on the role of combination immunotherapy with chemotherapy for the treatment of individual cancer. I think that's going to be practice changing. So, it's very timely, that we have experts like Matthew Powell, MD, who's coming from Washington University to speak about this topic.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More